Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24644087)

1.

Binding kinetics of a fluorescently labeled bisphosphonate as a tool for dynamic monitoring of bone mineral deposition in vivo.

Tower RJ, Campbell GM, Müller M, Will O, Glüer CC, Tiwari S.

J Bone Miner Res. 2014 Sep;29(9):1993-2003. doi: 10.1002/jbmr.2224.

PMID:
24644087
2.

Utilizing time-lapse micro-CT-correlated bisphosphonate binding kinetics and soft tissue-derived input functions to differentiate site-specific changes in bone metabolism in vivo.

Tower RJ, Campbell GM, Müller M, Glüer CC, Tiwari S.

Bone. 2015 May;74:171-81. doi: 10.1016/j.bone.2015.01.009. Epub 2015 Jan 19.

3.

A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.

Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, Clarke SL, Cullen DM, Lucas EA.

Bone. 2014 Jan;58:151-9. doi: 10.1016/j.bone.2013.10.005. Epub 2013 Oct 11.

PMID:
24125756
4.

Effects of osteoporosis medications on bone quality.

Benhamou CL.

Joint Bone Spine. 2007 Jan;74(1):39-47. Epub 2006 Nov 28. Review.

PMID:
17196423
6.

Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.

Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K.

Bone. 2008 Nov;43(5):894-900. doi: 10.1016/j.bone.2008.07.002. Epub 2008 Jul 18.

PMID:
18687415
8.
9.

Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice.

Andersson N, Lindberg MK, Ohlsson C, Andersson K, Ryberg B.

J Endocrinol. 2001 Sep;170(3):529-37.

10.

Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.

Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR.

Calcif Tissue Int. 2003 Apr;72(4):519-27. Epub 2003 Feb 10.

PMID:
12574877
11.

Compositional and material properties of rat bone after bisphosphonate and/or Strontium ranelate drug treatment.

Wu Y, Adeeb SM, Duke MJ, Munoz-Paniagua D, Doschak MR.

J Pharm Pharm Sci. 2013;16(1):52-64.

13.

Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.

Roelofs AJ, Stewart CA, Sun S, Błażewska KM, Kashemirov BA, McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP.

J Bone Miner Res. 2012 Apr;27(4):835-47. doi: 10.1002/jbmr.1543.

PMID:
22228189
15.

Differential transcriptional effects of PTH and estrogen during anabolic bone formation.

von Stechow D, Zurakowski D, Pettit AR, Müller R, Gronowicz G, Chorev M, Otu H, Libermann T, Alexander JM.

J Cell Biochem. 2004 Oct 15;93(3):476-90.

PMID:
15372627
16.

A rat osteoporotic spine model for the evaluation of bioresorbable bone cements.

Wang ML, Massie J, Perry A, Garfin SR, Kim CW.

Spine J. 2007 Jul-Aug;7(4):466-74. Epub 2007 Apr 6.

PMID:
17630145
17.

Tissue distribution and pharmacological potential of SM-16896, a novel oestrogen-bisphosphonate hybrid compound.

Tsushima N, Yabuki M, Harada H, Katsumata T, Kanamaru H, Nakatsuka I, Yamamoto M, Nakatsuka M.

J Pharm Pharmacol. 2000 Jan;52(1):27-37.

PMID:
10716600
19.

Drug-induced prevention of gastrectomy- and ovariectomy-induced osteopaenia in the young female rat.

Andersson N, Surve VV, Lehto-Axtelius D, Ohlsson C, Håkanson R, Andersson K, Ryberg B.

J Endocrinol. 2002 Dec;175(3):695-703.

20.

Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.

Compston JE.

Bone. 2007 Jun;40(6):1447-52. Epub 2006 Oct 12. Review.

PMID:
17045858
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk